<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379703</url>
  </required_header>
  <id_info>
    <org_study_id>PMOS-EAST-04-1</org_study_id>
    <nct_id>NCT01379703</nct_id>
  </id_info>
  <brief_title>Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use</brief_title>
  <acronym>KaleEAST</acronym>
  <official_title>Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      KaleEAST is a non-interventional, post-marketing observational study (PMOS) in which
      lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of the
      local marketing authorization with regards to dose, population and indication. No additional
      procedures (other than the standard of care) are to be applied to the patients.

      The KaleEAST PMOS was conducted in a prospective, single-arm, multicountry, multicenter
      format. The study was carried out in two (2) parts: the first part was initiated in 2004 with
      the lopinavir/ritonavir capsule formulation, the second part started in 2006 after the
      lopinavir/ritonavir tablets had become available in the participating countries.

      The aim of this post-marketing observational study was to obtain further data on clinical,
      biological, and virological outcomes, compliance and tolerability of Kaletra®-containing
      regimen during routine clinical use in the participating countries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As this study is observational in nature, subject follow-up was not specified by the protocol
      but was left to the judgment of each physician within the 18 months period, which defines the
      survey for each participant. For indicative purposes, follow-up of each participant should
      enable approximately 7 visits during this period. These visits will take place at average
      intervals of 3 months, apart from the first visit following inclusion (usually at the end of
      the first treatment month) and apart from visits required because of intercurrent events.
      Participant visits were assigned as follows: Baseline/Day 0 (start of lopinavir/ritonavir
      treatment), Month 1 (day 1 to day 45), Month 3 (day 46 to day 136), Month 6 (day 137 to day
      228), Month 9 (day 229 to day 319), Month 12 (day 320 to day 410), Month 15 (day 411 to day
      501), Month 18 (day 502 to day 593). Each participant is planned to be observed during
      his/her lopinavir/ritonavir capsule containing treatment regimen for a maximum period of 18
      months, and each participant is planned to be observed during his/her lopinavir/ritonavir
      tablet containing treatment regimen for a maximum period of 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 Count</measure>
    <time_frame>Baseline</time_frame>
    <description>CD4 lymphocyte count is a measure of a participant's immunologic health. Participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the number of CD4+ cells at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CD4 Count</measure>
    <time_frame>Baseline to 1 month</time_frame>
    <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CD4 Count</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CD4 Count</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CD4 Count</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CD4 Count</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CD4 Count</measure>
    <time_frame>Baseline to 15 months</time_frame>
    <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in CD4 Count</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Baseline</time_frame>
    <description>Viral load is a direct measure of the viral burden by providing a count of the number of HIV-RNA copies in blood (plasma). The number of HIV-RNA copies in the blood was measured at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>1 month</time_frame>
    <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>3 months</time_frame>
    <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>6 months</time_frame>
    <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>9 months</time_frame>
    <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>12 months</time_frame>
    <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>15 months</time_frame>
    <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>18 months</time_frame>
    <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Parameter Blood Glucose</measure>
    <time_frame>Baseline, 9 months, 18 months</time_frame>
    <description>Blood glucose laboratory values were assessed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Parameter Transaminases</measure>
    <time_frame>Baseline, 9 months, 18 months</time_frame>
    <description>Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory values were assessed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Parameter Lipids</measure>
    <time_frame>Baseline, 9 months, 18 months</time_frame>
    <description>A blood lipid panel consisting of total cholesterol, triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels was performed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reasons for Discontinuation of Lopinavir/Ritonavir</measure>
    <time_frame>9 months</time_frame>
    <description>For participants who discontinued lopinavir/ritonavir treatment, the reasons for discontinuation are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Discontinuation of Lopinavir/Ritonavir</measure>
    <time_frame>18 months</time_frame>
    <description>For participants who discontinued lopinavir/ritonavir treatment, the reasons for discontinuation are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance With Lopinavir/Ritonavir</measure>
    <time_frame>9 months</time_frame>
    <description>Participants reported whether they had missed doses of their antiretroviral treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance With Lopinavir/Ritonavir</measure>
    <time_frame>18 months</time_frame>
    <description>Participants reported whether they had missed any doses of their antiretroviral treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Observed on Treatment With Lopinavir/Ritonavir.</measure>
    <time_frame>18 months</time_frame>
    <description>Total number of adverse events with causal relationship (rated by Investigator as probably or possibly related) to lopinavir/ritonavir treatment.
All serious adverse events and non serious adverse events (0.2% or greater frequency) are summarized in the &quot;Reported Adverse Events&quot; section of this record.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2288</enrollment>
  <condition>HIV-1 Patients</condition>
  <arm_group>
    <arm_group_label>Single patients group</arm_group_label>
    <description>Single HIV-1 infected patients group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        KaleEAST is non-interventional, observational study in which Kaletra® is prescribed in the
        usual manner in accordance with the terms of the local marketing authorization with regard
        to dose, population and indication.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients infected by HIV-1 infection who are either:

          -  Antiretroviral treatment (ART) naive or

          -  Had failed or had been intolerant to one previous combined antiretroviral treatment
             (cART), not including a Protease inhibitor (PI) (first-line pretreated without a
             Protease inhibitor) or

          -  Had failed or had been intolerant to one previous antiretroviral treatment ART,
             including one Protease inhibitor (first-line pretreated with a Protease Inhibitor).

        A ritonavir-boosted Protease inhibitor PI is considered as treatment with one Protease
        inhibitor PI.

        Exclusion Criteria:

          -  Treatment with drugs at risk for interactions with lopinavir/ritonavir

          -  Uncontrolled AIDS defining disease

          -  Two or more previous Protease inhibitors (PIs)

          -  Participation in another study or clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Hojnik, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott International</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57102</name>
      <address>
        <city>Brno</city>
        <zip>639 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57054</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57055</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57056</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57052</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 5344</name>
      <address>
        <city>Prague 8</city>
        <zip>180 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57053</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40011</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 7576</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57050</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57048</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57049</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6124</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57047</name>
      <address>
        <city>Rechovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57051</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 7578</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6127</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10105</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6190</name>
      <address>
        <city>Bialystok</city>
        <zip>15540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56885</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56887</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56883</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56888</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56889</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56884</name>
      <address>
        <city>Poznan</city>
        <zip>61-285</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56886</name>
      <address>
        <city>Szczecin</city>
        <zip>71-455</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56882</name>
      <address>
        <city>Warsaw</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56890</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57064</name>
      <address>
        <city>Brasov</city>
        <zip>500174</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6194</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57062</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57063</name>
      <address>
        <city>Constanta</city>
        <zip>900708</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57067</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57068</name>
      <address>
        <city>Iasi</city>
        <zip>700116</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57065</name>
      <address>
        <city>Targu Mures</city>
        <zip>540394</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57066</name>
      <address>
        <city>Timisoara</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57022</name>
      <address>
        <city>Barnaul</city>
        <zip>658610</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56918</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454052</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56963</name>
      <address>
        <city>Chita</city>
        <zip>672000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56923</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56903</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620115</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56921</name>
      <address>
        <city>Irkutsk</city>
        <zip>664043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref #/Investigator 57104</name>
      <address>
        <city>Irkutsk</city>
        <zip>664043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57028</name>
      <address>
        <city>Ivanovo</city>
        <zip>153000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57036</name>
      <address>
        <city>Izhevsk</city>
        <zip>426067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56945</name>
      <address>
        <city>Kaliningrad</city>
        <zip>2360000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56909</name>
      <address>
        <city>Kazan</city>
        <zip>420000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57037</name>
      <address>
        <city>Kemerovo</city>
        <zip>650056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref #/Investigator 57105</name>
      <address>
        <city>Kemerovo</city>
        <zip>650056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56948</name>
      <address>
        <city>Khabarovsk</city>
        <zip>680029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56932</name>
      <address>
        <city>Khanty-Mansiysk</city>
        <zip>628002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref #/Investigator 57107</name>
      <address>
        <city>Kirov</city>
        <zip>57107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57030</name>
      <address>
        <city>Kostroma</city>
        <zip>156007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56943</name>
      <address>
        <city>Krasnodar</city>
        <zip>350015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56928</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref #/Investigator 57106</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57021</name>
      <address>
        <city>Kurgan</city>
        <zip>640007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57025</name>
      <address>
        <city>Lipetsk</city>
        <zip>398043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56944</name>
      <address>
        <city>Magnitogorsk</city>
        <zip>350015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56904</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6209</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56902</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57024</name>
      <address>
        <city>Murmansk</city>
        <zip>183047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56907</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56964</name>
      <address>
        <city>Norilsk</city>
        <zip>663318</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56929</name>
      <address>
        <city>Novokuznetsk</city>
        <zip>654031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56942</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56926</name>
      <address>
        <city>Noyabrsk</city>
        <zip>629806</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56915</name>
      <address>
        <city>Orenburg</city>
        <zip>460035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57031</name>
      <address>
        <city>Orenburg</city>
        <zip>460035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56930</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56911</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56906</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56905</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56931</name>
      <address>
        <city>Samara</city>
        <zip>443041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56913</name>
      <address>
        <city>Saratov</city>
        <zip>410009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57033</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56920</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57038</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56908</name>
      <address>
        <city>Surgut</city>
        <zip>628400</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56962</name>
      <address>
        <city>Togliatti</city>
        <zip>445846</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57034</name>
      <address>
        <city>Tula</city>
        <zip>300002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56947</name>
      <address>
        <city>Tver</city>
        <zip>170024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57035</name>
      <address>
        <city>Tver</city>
        <zip>170024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56910</name>
      <address>
        <city>Tyumen</city>
        <zip>628602</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56919</name>
      <address>
        <city>Tyumen</city>
        <zip>628602</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57029</name>
      <address>
        <city>Ufa</city>
        <zip>450077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56949</name>
      <address>
        <city>Ulan-Ude</city>
        <zip>670034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56914</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57027</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56916</name>
      <address>
        <city>Volgograd</city>
        <zip>400040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref #/Investigator 57103</name>
      <address>
        <city>Vologda</city>
        <zip>160002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 56946</name>
      <address>
        <city>Yakutsk</city>
        <zip>677004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57026</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 7579</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6208</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6199</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57042</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57043</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57045</name>
      <address>
        <city>Kyiv</city>
        <zip>01015</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 6191</name>
      <address>
        <city>Kyiv</city>
        <zip>01015</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57046</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57044</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57039</name>
      <address>
        <city>Odessa</city>
        <zip>565031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 57040</name>
      <address>
        <city>Simferopol</city>
        <zip>95006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Georgia</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <results_first_submitted>August 9, 2011</results_first_submitted>
  <results_first_submitted_qc>August 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2011</results_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 infected patients</keyword>
  <keyword>Protease inhibitor</keyword>
  <keyword>Kaletra®</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was carried out in two parts. The first part was initiated in 2004 with the lopinavir/ritonavir capsule formulation (Part I) and the second part (Part II) started in 2006 after the tablet formulation became available in participating countries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tablets and Capsules or Oral Solution</title>
          <description>HIV-1 infected participants who received both tablet and capsule formulations or oral solution.</description>
        </group>
        <group group_id="P2">
          <title>Capsule Formulation</title>
          <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
        </group>
        <group group_id="P3">
          <title>Tablet Formulation</title>
          <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Start Through 9 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66">Participants taking lopinavir/ritonavir tablets/capsules or oral solution during the study (66/2288)</participants>
                <participants group_id="P2" count="1206">Participants taking the lopinavir/ritonavir capsule formulation (only) during study (1206/2288)</participants>
                <participants group_id="P3" count="1016">Participants taking the lopinavir/ritonavir tablet formulation (only) during study (1016/2288)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="1084">Participants taking the capsule formulation were followed for an additional 9 months (up to 18 mos).</participants>
                <participants group_id="P3" count="873"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tuberculosis/TB treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication not available</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor general condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Increased triglycerides</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason unknown</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>9 Months Through 18 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants in this subgroup were followed for 9 months.</participants>
                <participants group_id="P2" count="1084">Participants taking the capsule formulation were followed for an additional 9 months (up to 18 mos).</participants>
                <participants group_id="P3" count="0">Participants in this subgroup were followed for 9 months.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="854"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="230"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tuberculosis/TB treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fatigue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Unknown</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Study Population</title>
          <description>HIV-1 infected participants who received lopinavir/ritonavir (any formulation) during any part of the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2288"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD4 Count</title>
        <description>CD4 lymphocyte count is a measure of a participant's immunologic health. Participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the number of CD4+ cells at baseline.</description>
        <time_frame>Baseline</time_frame>
        <population>Mean CD4 count is based on number of participants in each group who had CD4 count results at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count</title>
          <description>CD4 lymphocyte count is a measure of a participant's immunologic health. Participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the number of CD4+ cells at baseline.</description>
          <population>Mean CD4 count is based on number of participants in each group who had CD4 count results at Baseline.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="1165"/>
                <count group_id="O3" value="993"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229.9" spread="194.2"/>
                    <measurement group_id="O2" value="208.8" spread="187.2"/>
                    <measurement group_id="O3" value="246.8" spread="194.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in CD4 Count</title>
        <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
        <time_frame>Baseline to 1 month</time_frame>
        <population>Change from baseline analysis is based on participants with CD4 count results available at 1 month.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Count</title>
          <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
          <population>Change from baseline analysis is based on participants with CD4 count results available at 1 month.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="670"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.7" spread="185.1"/>
                    <measurement group_id="O2" value="277.1" spread="195.7"/>
                    <measurement group_id="O3" value="296.1" spread="172.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" spread="137.4"/>
                    <measurement group_id="O2" value="54.9" spread="158.3"/>
                    <measurement group_id="O3" value="70.6" spread="113.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in CD4 Count</title>
        <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>Change from baseline analysis is based on participants with CD4 count results available at 3 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Count</title>
          <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
          <population>Change from baseline analysis is based on participants with CD4 count results available at 3 months.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1633"/>
                <count group_id="O2" value="838"/>
                <count group_id="O3" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323.9" spread="219.3"/>
                    <measurement group_id="O2" value="310.1" spread="227.9"/>
                    <measurement group_id="O3" value="332.4" spread="206.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" spread="162.9"/>
                    <measurement group_id="O2" value="97.7" spread="188.7"/>
                    <measurement group_id="O3" value="93.2" spread="123.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in CD4 Count</title>
        <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Change from baseline analysis is based on participants with CD4 count results available at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Count</title>
          <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
          <population>Change from baseline analysis is based on participants with CD4 count results available at 6 months.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1533"/>
                <count group_id="O2" value="780"/>
                <count group_id="O3" value="699"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.5" spread="248.9"/>
                    <measurement group_id="O2" value="333.4" spread="219.8"/>
                    <measurement group_id="O3" value="382.0" spread="271.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.4" spread="197.6"/>
                    <measurement group_id="O2" value="117.1" spread="182.5"/>
                    <measurement group_id="O3" value="131.6" spread="216.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in CD4 Count</title>
        <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
        <time_frame>Baseline to 9 months</time_frame>
        <population>Change from baseline analysis is based on participants with CD4 count results available at 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Count</title>
          <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
          <population>Change from baseline analysis is based on participants with CD4 count results available at 9 months.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1410"/>
                <count group_id="O2" value="713"/>
                <count group_id="O3" value="645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count at 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384.1" spread="221.4"/>
                    <measurement group_id="O2" value="363.5" spread="222.2"/>
                    <measurement group_id="O3" value="395.0" spread="209.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.5" spread="174.4"/>
                    <measurement group_id="O2" value="144.8" spread="191.7"/>
                    <measurement group_id="O3" value="156.0" spread="151.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in CD4 Count</title>
        <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on participants receiving capsule formulation with CD4 count results available at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Count</title>
          <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on participants receiving capsule formulation with CD4 count results available at 12 months.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.0" spread="216.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.4" spread="201.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in CD4 Count</title>
        <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
        <time_frame>Baseline to 15 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on participants receiving capsule formulation with CD4 count results available at 15 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Count</title>
          <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on participants receiving capsule formulation with CD4 count results available at 15 months.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count at 15 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.6" spread="240.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.8" spread="228.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in CD4 Count</title>
        <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
        <time_frame>Baseline to 18 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on participants receiving capsule formulation with CD4 count results available at 18 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Count</title>
          <description>Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on participants receiving capsule formulation with CD4 count results available at 18 months.</population>
          <units>cells per mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean CD4 count at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429.7" spread="249.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD4 count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.2" spread="228.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load is a direct measure of the viral burden by providing a count of the number of HIV-RNA copies in blood (plasma). The number of HIV-RNA copies in the blood was measured at baseline.</description>
        <time_frame>Baseline</time_frame>
        <population>Mean viral load is based on number of participants in each group who had laboratory results for viral load at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load is a direct measure of the viral burden by providing a count of the number of HIV-RNA copies in blood (plasma). The number of HIV-RNA copies in the blood was measured at baseline.</description>
          <population>Mean viral load is based on number of participants in each group who had laboratory results for viral load at baseline.</population>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1572"/>
                <count group_id="O2" value="739"/>
                <count group_id="O3" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean viral load</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="1.26"/>
                    <measurement group_id="O2" value="4.49" spread="1.17"/>
                    <measurement group_id="O3" value="4.43" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="1.08"/>
                    <measurement group_id="O2" value="3.42" spread="1.07"/>
                    <measurement group_id="O3" value="3.19" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="995"/>
                <count group_id="O2" value="469"/>
                <count group_id="O3" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="1.00"/>
                    <measurement group_id="O2" value="2.86" spread="0.97"/>
                    <measurement group_id="O3" value="2.54" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1093"/>
                <count group_id="O2" value="506"/>
                <count group_id="O3" value="544"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.89"/>
                    <measurement group_id="O2" value="2.62" spread="0.88"/>
                    <measurement group_id="O3" value="2.21" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
        <time_frame>9 months</time_frame>
        <population>Change from baseline analysis is based on last observation carried forward for total study population (N=1341) and tablet formulation group (N=677).</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
          <population>Change from baseline analysis is based on last observation carried forward for total study population (N=1341) and tablet formulation group (N=677).</population>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="471"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean viral load at 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.96"/>
                    <measurement group_id="O2" value="2.65" spread="1.02"/>
                    <measurement group_id="O3" value="2.24" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in viral load</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="1.42"/>
                    <measurement group_id="O2" value="NA">Change from baseline LOCF analysis for participants receiving capsule formulation was performed at 18 months.</measurement>
                    <measurement group_id="O3" value="-2.21" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
        <time_frame>12 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
        <time_frame>15 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Viral Load</title>
        <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
        <time_frame>18 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on last observation carried forward (N=660).</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (number of HIV-RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months. Change from baseline analysis is based on last observation carried forward (N=660).</population>
          <units>Log10 copies per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean viral load at 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in viral load</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Parameter Blood Glucose</title>
        <description>Blood glucose laboratory values were assessed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
        <time_frame>Baseline, 9 months, 18 months</time_frame>
        <population>Analysis was based on participants with laboratory values at each time point. Only participants receiving lopinavir/ritonavir capsules were planned to be followed after 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter Blood Glucose</title>
          <description>Blood glucose laboratory values were assessed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
          <population>Analysis was based on participants with laboratory values at each time point. Only participants receiving lopinavir/ritonavir capsules were planned to be followed after 9 months.</population>
          <units>millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1831"/>
                <count group_id="O2" value="875"/>
                <count group_id="O3" value="899"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="2.05"/>
                    <measurement group_id="O2" value="4.89" spread="2.83"/>
                    <measurement group_id="O3" value="4.85" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="1.42"/>
                    <measurement group_id="O2" value="4.87" spread="1.38"/>
                    <measurement group_id="O3" value="4.99" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only participants who received lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                    <measurement group_id="O2" value="5.07" spread="2.64"/>
                    <measurement group_id="O3" value="NA">Only participants who received lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Parameter Transaminases</title>
        <description>Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory values were assessed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
        <time_frame>Baseline, 9 months, 18 months</time_frame>
        <population>Analysis was based on participants with laboratory values at each time point. Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter Transaminases</title>
          <description>Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) laboratory values were assessed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
          <population>Analysis was based on participants with laboratory values at each time point. Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
          <units>international units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2288"/>
                <count group_id="O2" value="1206"/>
                <count group_id="O3" value="1016"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="37.1"/>
                    <measurement group_id="O2" value="36.8" spread="32.1"/>
                    <measurement group_id="O3" value="41.4" spread="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="33.0"/>
                    <measurement group_id="O2" value="34.8" spread="29.6"/>
                    <measurement group_id="O3" value="36.0" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                    <measurement group_id="O2" value="36.4" spread="30.8"/>
                    <measurement group_id="O3" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="40.3"/>
                    <measurement group_id="O2" value="39.6" spread="38.7"/>
                    <measurement group_id="O3" value="42.6" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="52.5"/>
                    <measurement group_id="O2" value="40.8" spread="44.8"/>
                    <measurement group_id="O3" value="39.0" spread="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT - 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                    <measurement group_id="O2" value="42.0" spread="44.8"/>
                    <measurement group_id="O3" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Laboratory Parameter Lipids</title>
        <description>A blood lipid panel consisting of total cholesterol, triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels was performed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
        <time_frame>Baseline, 9 months, 18 months</time_frame>
        <population>Analysis was based on participants with laboratory values at each time point. Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter Lipids</title>
          <description>A blood lipid panel consisting of total cholesterol, triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels was performed at baseline and scheduled study visits. Normal ranges are based on the standards for individual facilities in each country.</description>
          <population>Analysis was based on participants with laboratory values at each time point. Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
          <units>millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2288"/>
                <count group_id="O2" value="1206"/>
                <count group_id="O3" value="1016"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="1.50"/>
                    <measurement group_id="O2" value="4.48" spread="1.68"/>
                    <measurement group_id="O3" value="4.28" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="1.81"/>
                    <measurement group_id="O2" value="5.07" spread="2.36"/>
                    <measurement group_id="O3" value="4.89" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol - 18 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                    <measurement group_id="O2" value="5.01" spread="1.29"/>
                    <measurement group_id="O3" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.84"/>
                    <measurement group_id="O2" value="2.17" spread="1.45"/>
                    <measurement group_id="O3" value="1.19" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.98"/>
                    <measurement group_id="O2" value="2.08" spread="1.64"/>
                    <measurement group_id="O3" value="1.32" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol - 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                    <measurement group_id="O2" value="2.04" spread="1.94"/>
                    <measurement group_id="O3" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="1.07"/>
                    <measurement group_id="O2" value="2.87" spread="1.10"/>
                    <measurement group_id="O3" value="2.29" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="1.07"/>
                    <measurement group_id="O2" value="3.11" spread="1.18"/>
                    <measurement group_id="O3" value="2.51" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol - 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                    <measurement group_id="O2" value="3.09" spread="1.14"/>
                    <measurement group_id="O3" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="1.06"/>
                    <measurement group_id="O2" value="1.66" spread="1.11"/>
                    <measurement group_id="O3" value="1.64" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="1.46"/>
                    <measurement group_id="O2" value="2.21" spread="1.49"/>
                    <measurement group_id="O3" value="2.17" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides - 18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                    <measurement group_id="O2" value="2.13" spread="1.35"/>
                    <measurement group_id="O3" value="NA">Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Discontinuation of Lopinavir/Ritonavir</title>
        <description>For participants who discontinued lopinavir/ritonavir treatment, the reasons for discontinuation are provided.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Discontinuation of Lopinavir/Ritonavir</title>
          <description>For participants who discontinued lopinavir/ritonavir treatment, the reasons for discontinuation are provided.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2288"/>
                <count group_id="O2" value="1206"/>
                <count group_id="O3" value="1016"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal by Subject</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Tuberculosis/TB treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Medication not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Poor general condition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Increased triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Noncompliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Discontinuation of Lopinavir/Ritonavir</title>
        <description>For participants who discontinued lopinavir/ritonavir treatment, the reasons for discontinuation are provided.</description>
        <time_frame>18 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Discontinuation of Lopinavir/Ritonavir</title>
          <description>For participants who discontinued lopinavir/ritonavir treatment, the reasons for discontinuation are provided.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules were planned to be followed past 9 months.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal by Subject</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Tuberculosis/TB treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Noncompliance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Medication not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other - Increased triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reason unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance With Lopinavir/Ritonavir</title>
        <description>Participants reported whether they had missed doses of their antiretroviral treatment.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Lopinavir/Ritonavir</title>
          <description>Participants reported whether they had missed doses of their antiretroviral treatment.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2288"/>
                <count group_id="O2" value="1206"/>
                <count group_id="O3" value="1016"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reported never missing a dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1377"/>
                    <measurement group_id="O2" value="729"/>
                    <measurement group_id="O3" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported missing one or more doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="853"/>
                    <measurement group_id="O2" value="459"/>
                    <measurement group_id="O3" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Information not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance With Lopinavir/Ritonavir</title>
        <description>Participants reported whether they had missed any doses of their antiretroviral treatment.</description>
        <time_frame>18 months</time_frame>
        <population>Only participants receiving lopinavir/ritonavir capsules for followed for up to 18 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation of lopinavir/ritonavir during Part 1 or Part II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Lopinavir/Ritonavir</title>
          <description>Participants reported whether they had missed any doses of their antiretroviral treatment.</description>
          <population>Only participants receiving lopinavir/ritonavir capsules for followed for up to 18 months.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reported never missing a dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported missing one or more doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Information not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Observed on Treatment With Lopinavir/Ritonavir.</title>
        <description>Total number of adverse events with causal relationship (rated by Investigator as probably or possibly related) to lopinavir/ritonavir treatment.
All serious adverse events and non serious adverse events (0.2% or greater frequency) are summarized in the &quot;Reported Adverse Events&quot; section of this record.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total Study Population</title>
            <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
          </group>
          <group group_id="O2">
            <title>Capsule Formulation</title>
            <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>Tablet Formulation</title>
            <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Observed on Treatment With Lopinavir/Ritonavir.</title>
          <description>Total number of adverse events with causal relationship (rated by Investigator as probably or possibly related) to lopinavir/ritonavir treatment.
All serious adverse events and non serious adverse events (0.2% or greater frequency) are summarized in the &quot;Reported Adverse Events&quot; section of this record.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2288"/>
                <count group_id="O2" value="1206"/>
                <count group_id="O3" value="1016"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of AEs with causal relationship</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study start through 9 months for all participants, and study start through 18 months for participants receiving lopinavir/ritonavir capsules.</time_frame>
      <desc>Adverse events (AEs) and Serious AEs occurring during the study were recorded. Serious AEs were reported from the time the physician obtained the patient's authorization to use and disclose information (or the patient's informed consent) until 30 days following intake of the last dose of the physician-prescribed lopinavir/ritonavir treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Total Study Population</title>
          <description>HIV-1 infected participants who received any formulation of lopinavir/ritonavir during Parts I or II of the study (including 66 participants who received both tablet and capsule formulations, or oral solution).</description>
        </group>
        <group group_id="E2">
          <title>Capsule Formulation</title>
          <description>Participants who received the capsule formulation (only) of lopinavir/ritonavir during Part I or Part II of the study.</description>
        </group>
        <group group_id="E3">
          <title>Tablet Formulation</title>
          <description>Participants who received the tablet formulation (only) of lopinavir/ritonavir during Parts I or II of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Exophthalmos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Encephalitis cytomegalovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Mycobacteria test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <description>Adverse event occurred in one of the 66 participants receiving both capsules and tablets, or oral solution.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <description>One of the two adverse events occurred in one of the 66 participants receiving both capsules and tablets, or oral solution.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Thrombectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.2</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>One or more adverse events occurred in the 66 participants receiving both capsules and tablets, or oral solution.</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>One or more adverse events occurred in the 66 participants receiving both capsules and tablets, or oral solution.</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>One or more adverse events occurred in the 66 participants receiving both capsules and tablets, or oral solution.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>One or more adverse events occurred in the 66 participants receiving both capsules and tablets, or oral solution.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1016"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1016"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

